What isKPVFDA Status, Evidence and Risks (2026)

What KPV is

KPV is three amino acids: lysine, proline and valine (Lys-Pro-Val). It matches amino acids 11 to 13 of alpha-MSH, a hormone the body makes ³.

FDA reviewed two forms, KPV free base and KPV acetate. "KPV" is a common name. It has no official US or international drug name, and FDA called both forms "not well-characterized," with no impurity, aggregate or microbial test data ³.

Melanotan II comes from the same parent hormone and acts on melanocortin receptors, the ones tied to skin color. In lab research, KPV did not appear to bind them. It showed anti-inflammatory effects instead ³.

Where FDA stands

• Category 2, until Apr 2026. KPV sat on FDA's list of compounding substances that may present significant safety risks. It came off in Apr 2026, one of 12 peptides removed after their nominators withdrew them ^1,4.
• Removal approved nothing. KPV is not approved by FDA for any use and is not on the 503A bulks list, the list a pharmacy needs to compound a substance that is not part of an approved drug ². More in Are Peptides Legal?
• FDA staff said no. On Jul 23, 2026, FDA told its advisory committee: "FDA is proposing that KPV (free base) and KPV acetate NOT be included on the 503A Bulks List" ³.
• The panel said yes. The Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend it anyway. KPV was voted on together with BPC-157 and TB-500 ^5,6.
• The vote is advice. FDA decides. Adding KPV to the list would take notice-and-comment rulemaking ⁵.
• HHS policy, filed Oct 28, 2026. HHS says it won't take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound KPV acetate for use on the skin or by mouth, when the policy's conditions are met ^7,8. It is interim and not binding, and it approves nothing. It lasts while the 503A list goes through rulemaking, and it publishes in the Federal Register Oct 30, 2026 ⁷. Read the full breakdown in HHS's Oct 28 peptide policy.

What the research shows

Evidence type: preclinical only (animal and cell research). FDA's literature search "did not identify data, such as clinical studies, on the use of KPV in humans" ³.

KPV was nominated as a 0.1% cream and gel, for wound healing and inflammatory skin conditions such as psoriasis and eczema ³. Websites sell it for inflammatory bowel disease, gut health, nerve damage and stroke, among other uses ³.

For those uses, FDA said "there is a lack of evidence to evaluate the effectiveness of KPV" ³. On the skin data, FDA noted that poor absorption might limit harm from the body taking it in, and might also limit whether a cream does anything ³.

Any gut claim you see for KPV rests on animal or cell work. No study in people has tested it.

Known risks and FDA's concerns

FDA's stated concerns first ^1,3:

• No human exposure data. FDA "has not identified any human exposure data on drug products containing KPV administered via any route of administration."
• Unknown safety. "Potential safety risks associated with the use in humans are unknown."
• No toxicity studies. None submitted, none found in the literature.
• Immune reactions and clumping. Not assessed. Nobody has tested for them.
• Unclear naming. Products online often do not say which form they contain, and inconsistent names make that harder to check.

FDA's adverse event databases returned no KPV reports. FDA said that does not mean the substance is safe ³. With no human studies, there is no reliable side effect list.

Why it's sold online anyway

KPV is easy to find labeled "research use only" or "not for human consumption." That label is the seller saying the product is not made for people.

What those products skip: a prescriber reviewing your health history, a licensed pharmacy, and quality testing for human use. FDA found no compounded KPV product in the published literature or in outsourcing facility reports, and said the extent of its use in compounding is unknown ³. More on the difference: Prescription vs Research Peptides.

Other peptides on this shelf: BPC-157 and TB-500, voted on in the same 8 to 6 tally. Side by side: BPC-157 vs TB-500.

Asked a lot.

The sources.

1. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). Read it
2. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). Read it
3. FDA. Presentation to the Pharmacy Compounding Advisory Committee, including KPV (Jul 23, 2026). Read it
4. Frier Levitt. FDA Peptides "Do Not Compound" List Update (Apr 16, 2026). Read it
5. Bass Berry. FDA Advisory Committee Recommends Six Peptides for Compounding (Jul 31, 2026). Read it
6. AJMC. FDA Panel Backs 6 Peptides for Compounding (Jul 31, 2026). Read it
7. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026; scheduled to publish in the Federal Register Oct 30, 2026). Read it
8. Hyman, Phelps and McNamara, FDA Law Blog. The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion … Not the Finish Line (Oct 28, 2026). Read it